Who is sponsoring NCT02336672?

NCT02336672 is sponsored by IRCCS San Raffaele.

What drugs are being tested in NCT02336672?

Interventions in NCT02336672: Cryothermal ablation.

What condition does NCT02336672 study?

NCT02336672 studies Pancreatic Adenocarcinoma Non-resectable.

Is NCT02336672 still recruiting?

NCT02336672 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT02336672

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

Completed NA Last updated 28 September 2023

What this trial tests

NA trial testing Cryothermal ablation in Pancreatic Adenocarcinoma Non-resectable in 66 participants. Completed in 31 December 2021.

Timeline

11 November 2014

Primary endpoint
31 December 2018

31 December 2021

Quick facts

Lead sponsor	IRCCS San Raffaele
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	11 November 2014
Primary completion	31 December 2018
Estimated completion	31 December 2021
Sites	1 location across Italy

Drugs / interventions tested

Cryothermal ablation

Conditions studied

Pancreatic Adenocarcinoma Non-resectable — all drugs for Pancreatic Adenocarcinoma Non-resectable →

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

Adults 18 to 80, any sex, with Pancreatic Adenocarcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with locally advanced tumour, neoadjuvant treatment has been proposed in various modalities as a way to decrease size and downstage the tumour leading to a re-sectable disease. The HybridTherm probe (HTP), (ERBE Elektromedizin GmbH, Tübingen, Germany) combines bipolar RF-ablation with cryogenic induced cooling. A bipolar radiofrequency system creates ablation with less collateral thermal damage than standard monopolar systems but with the trade-off to lose overall efficiency.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.
Spadi R, Brusa F, Ponzetti A, Chiappino I, et al · · 2016 · cited 64× · PMID 26862489 · DOI 10.5306/wjco.v7.i1.27
Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial.
Testoni SGG, Petrone MC, Reni M, Rossi G, et al · · 2021 · cited 11× · PMID 34572743 · DOI 10.3390/cancers13184512
Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma.
Testoni SGG, Minici C, Benetti E, Clemente F, et al · · 2023 · cited 5× · PMID 37509365 · DOI 10.3390/cancers15143704

Verify or expand the search:

Other recruiting trials for Pancreatic Adenocarcinoma Non-resectable

Currently open trials in the same condition.

NCT07481383 — A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly o · Phase 1 · recruiting
NCT06090916 — Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic C · NA · active not recruiting
NCT05524090 — PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer · recruiting

Other IRCCS San Raffaele trials

Trials by the same sponsor.

NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02336672 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02336672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing